Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin, nervous system, and other parts of the body. The condition, formerly called Von Recklinghausen disease, causes changes in ...

Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

The risks of 4 types of skin cancers were investigated among patients who have neurofibromatosis type 1, a multisystem autosomal dominant genetic syndrome characterized by loss of neurofibromin. Basal ...

Neurofibromatosis type 1 (NF1) is a hereditary condition arising from mutations in the NF1 gene, which encodes neurofibromin—a key regulator of cellular signalling and neural development. Children ...

Neurofibromatosis type 1 (NF1) is a genetically inherited disorder that manifests in a broad spectrum of clinical features including dermatological, neurological, skeletal and notably, ocular ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Neurofibromatosis (NF) refers to a group of genetic conditions that cause tumors to grow on nerves throughout the body. The term “NF” includes neurofibromatosis type 1 (NF1) and all types of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Mirdametinib is an investigational mitogen-activated ...

Mirdametinib received FDA approval for NF1 patients aged 2 and older, showing efficacy in reducing PN volume and improving quality of life. Conditional European approval was granted for mirdametinib, ...

A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has studied alterations in the KRAS gene in colorectal cancer by combining genomic ...

The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ...

Rapid NF1-PN growth and symptom progression are typical during early childhood, but disease progression can occur at any time. Neurofibromatosis type 1 (NF1) is a genetic condition that causes changes ...